يحاول ذهب - حر
OpenAI, Microsoft Rift Hinges on How Smart AI Can Get
June 27, 2025
|Mint Chennai
The future of the OpenAI-Microsoft partnership—one of the most storied in tech history—hinges in part on the meaning of an amorphous AI buzzword that divides many in the industry.
The contract between the tech partners, who have been locked in acrimonious negotiations, stipulates that when OpenAI's systems reach "artificial general intelligence," or AGI, the startup will be able to limit Microsoft's access to its future technology.
Microsoft is fighting hard to prevent that.
Many AI experts see AGI as the point at which generative AI systems achieve humanlike intelligence, but OpenAI and Microsoft are at odds over the issue.
OpenAI executives, including Sam Altman, believe they are close to being able to declare that their AI tools have achieved the AGI level of proficiency, according to people familiar with the matter.
Microsoft Chief Executive Satya Nadella has expressed skepticism that reaching such a benchmark is possible.
Their disagreement mirrors a debate among Silicon Valley's elite about just how sophisticated cutting-edge tools can become.
"We have a long-term, productive partnership that has delivered amazing AI tools for everyone. Talks are ongoing, and we are optimistic we will continue to build together for years to come," representatives for both companies said in a statement.
هذه القصة من طبعة June 27, 2025 من Mint Chennai.
اشترك في Magzter GOLD للوصول إلى آلاف القصص المتميزة المنسقة، وأكثر من 9000 مجلة وصحيفة.
هل أنت مشترك بالفعل؟ تسجيل الدخول
المزيد من القصص من Mint Chennai
Mint Chennai
Lenskart wants artificial intelligence to test your eyes
It expects AI-enabled eye testing to become the default foundational layer of eyecare delivery
3 mins
January 13, 2026
Mint Chennai
More companies to take a hit as labour codes debut
Reworked gratuity and leave encashments spell additional expenses for India Inc
2 mins
January 13, 2026
Mint Chennai
HC lifts ban on Zydus cancer biosimilar till patent expiry
In a relief for Zydus Lifesciences, a division bench of the Delhi High Court on Monday allowed the drugmaker to sell and market its biosimilar of the anticancer drug nivolumab in India, citing public interest.
2 mins
January 13, 2026
Mint Chennai
Trump’s investigation of Powell is also a warning to the next Fed chair
The criminal investigation into Federal Reserve Chair Jerome Powell isn’t ultimately about the Fed’s headquarters, or Powell, or even interest rates.
3 mins
January 13, 2026
Mint Chennai
States flag Almont-Kid syrup as tests find contaminants
Syrup found ‘Not of Standard Quality’ with contaminants like toxic ethylene glycol
1 mins
January 13, 2026
Mint Chennai
India at 100: Our choices today will define the next two decades
India's 2047 ambition is not guaranteed but achievable if we address all the potential pitfalls along our development path
4 mins
January 13, 2026
Mint Chennai
Now, inheritance works without probate—but why it still matters
Heirs can now act on a valid will without court cases, easing delays and unlocking assets in undisputed cases
6 mins
January 13, 2026
Mint Chennai
Why VCs have a new deep-tech playbook
where fundraising starts to drag,\" said Chand.
1 min
January 13, 2026
Mint Chennai
TCS, HCLTech deliver Q3 revenue surprise
clearer.
2 mins
January 13, 2026
Mint Chennai
US productivity is rising and it risks warping monetary policy
America's neutral rate ought to be going up but will the Fed listen?
3 mins
January 13, 2026
Listen
Translate
Change font size
